Overview
- Discusses molecular mechanisms of total or partial loss of the MHC class I antigens in cancer cells
- Explains the role of MHC class I defects in cancer progression
- Shows the correlation of MHC class I altered phenotypes with resistance to Immunotherapy ?
- Includes supplementary material: sn.pub/extras
Part of the book series: SpringerBriefs in Cancer Research (BRIEFSCANCER, volume 1)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
About this book
Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy.
Similar content being viewed by others
Keywords
Table of contents (5 chapters)
-
Front Matter
Authors and Affiliations
About the authors
Teresa Cabrera Castillo, Ph.D., MD., is a Full Professor at the Department of Biochemistry, Molecular Biology, and Immunology at the University of Granada and a Medical Immunology Specialist at Hospital Universitario Virgen de las Nieves. Natalia Aptsiauri, Ph.D., MD., is a Senior Staff Scientist at the Department of Clinical Analysis and Immunology, University Hospital Virgen de las Nieves Angel Miguel Garcia Lora, Ph.D., is a Senior Staff Scientist at the Department of Clinical Analysis and Immunology, University Hospital Virgen de las Nieves Please see attached CVs for more detail.
Bibliographic Information
Book Title: MHC Class I Antigens In Malignant Cells
Book Subtitle: Immune Escape And Response To Immunotherapy
Authors: Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera
Series Title: SpringerBriefs in Cancer Research
DOI: https://doi.org/10.1007/978-1-4614-6543-0
Publisher: Springer New York, NY
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Maria Teresa Cabrera Castillo 2013
Softcover ISBN: 978-1-4614-6542-3Published: 22 February 2013
eBook ISBN: 978-1-4614-6543-0Published: 26 February 2013
Series ISSN: 2194-1173
Series E-ISSN: 2194-1181
Edition Number: 1
Number of Pages: VIII, 51
Number of Illustrations: 3 b/w illustrations, 14 illustrations in colour
Topics: Cancer Research, Immunology, Molecular Medicine